Responses
Clinical and epidemiological research
Extended report
Canakinumab treatment for patients with active recurrent or chronic TNF receptor-associated periodic syndrome (TRAPS): an open-label, phase II study
Compose a Response to This Article
Other responses
No responses have been published for this article.